Menetrier disease is a condition defined by hypertrophy of the gastric mucosa along with protein loss. It is a complex and severe abnormality that is not very common, and it has an association with stomach cancer. Protheragen leads the market in research services related to preclinical development drugs for Menetrier disease and offers a complete range of services from diagnostic service to therapy and even disease model development.

Overview of Menetrier Disease

Menetrier disease is a rare condition that occurs in the proximal stomach, whereby the giant mucosal folds, acid secretion is lessened, and protein loss occurs which is accompanied by hypoalbuminemia. Menetrier disease has also been referred to as hypoproteinemic hypertrophic gastropathy and giant hypertrophic gastritis. Up to now, there are no more than 1000 documented instances of it.

Fig.1 Characteristics of Menetrier disease. (Pepa, P., et al., 2021)

Pathogenesis of Menetrier Disease

Menetrier disease occurs in younger children and is self-limiting. It is associated with cytomegalovirus infection. However, in adults, it is associated with Helicobacter pylori infection. Excess TGF-alpha in the superficial gastric epithelium could contribute to etiopathogenesis. Under the influence of TGF-alpha, acid production is decreased. The decrease in acid is owing to a direct action on parietal cells and indirect action through stimulation of somatostatin release. This leads to hypersecretion of mucus and consequently, malabsorption of nutrients, electrolytes, and vitamins in the small bowel.

Therapeutics Development for Menetrier Disease

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

With a specialization in drug research and development for Menetrier disease, our team comprises professionals with thorough knowledge and experience. Each client has particular needs and we aim to ensure that those are met. We provide a full range of services from the development of diagnostics and therapeutics as well as the development of models for the disease.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

Before trials on human subjects begin, researchers must ensure that the drugs designed are effective and safe. To that end, a variety of research exists that uses animal models in the preliminary phases of drug development which helps researchers in testing and analyzing therapeutics. Our company builds custom-tailored animal models for Menetrier disease research so that accuracy and relevance are maintained during preclinical studies.

Genetically Engineering Model

Employ genetically modified animal models to mimic some features of Menetrier disease, such as gastric mucosal hypertrophy and glandular hyperplasia.

• TGFA overexpression model
• H/K-ATPase beta subunit deficient model

Apart from that, Protheragen offers pharmacokinetic and biosafety evaluation services as part of our drug development service portfolio. Benefiting from our experience and technology, as well as from our innovative high-quality solutions, enable us to center on your needs. If you have any interest in our services, please feel free to contact us.

Reference

• Pepa, Pablo et al. "Menetrier's disease. A diagnostic and therapeutic challenge." Medicina 81.3 (2021): 470-473.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.